No relationship between drug transporter genetic variants and tenofovir plasma concentrations or changes in glomerular filtration rate in HIV-infected adults.
作者信息
Sirirungsi Wasna, Urien Saik, Harrison Linda, Kamkon Jiraporn, Tawon Yardpiroon, Luekamlung Nuananong, Thongpaen Suchart, Nilmanat Ampaipith, Jourdain Gonzague, Lallemant Marc, Le Coeur Sophie, Ngo-Giang-Huong Nicole, Owen Andrew, Cressey Tim R
机构信息
*Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand †EAU08 University Paris Descartes and CIC1419 Inserm, Paris, France ‡Hopital Cochin, Assistance Publique-Hopitaux de Paris, Paris, France §Unite de Recherche clinique, AP-HP, Hopital Tarnier, Paris, France ‖Institut de Recherche pour le Développement (IRD) UMI 174-Program for HIV Prevention and Treatment (PHPT), Marseille, France ¶Lamphun Hospital, Lamphun, Thailand #Maha Sarakham Hospital, Maha Sarakham, Thailand **Hat Yai Hospital, Songkhla, Thailand ††Harvard School of Public Health, Boston, MA ‡‡Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom.
出版信息
J Acquir Immune Defic Syndr. 2015 Apr 1;68(4):e56-9. doi: 10.1097/QAI.0000000000000504.
Abstract
摘要
相似文献
1
No relationship between drug transporter genetic variants and tenofovir plasma concentrations or changes in glomerular filtration rate in HIV-infected adults.
J Acquir Immune Defic Syndr. 2015 Apr 1;68(4):e56-9. doi: 10.1097/QAI.0000000000000504.
2
ABCC2*1C and plasma tenofovir concentration are correlated to decreased glomerular filtration rate in patients receiving a tenofovir-containing antiretroviral regimen.
J Antimicrob Chemother. 2014 Aug;69(8):2195-201. doi: 10.1093/jac/dku129. Epub 2014 Apr 30.
3
Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study.
Clin Infect Dis. 2009 Jun 1;48(11):e108-16. doi: 10.1086/598507.
4
Association of higher plasma vitamin D binding protein and lower free calcitriol levels with tenofovir disoproxil fumarate use and plasma and intracellular tenofovir pharmacokinetics: cause of a functional vitamin D deficiency?
Antimicrob Agents Chemother. 2013 Nov;57(11):5619-28. doi: 10.1128/AAC.01096-13. Epub 2013 Sep 3.
5
[Conclusions. Tenofovir].
Enferm Infecc Microbiol Clin. 2008 Jun;26 Suppl 8:62-4. doi: 10.1157/13126273.
6
Unlikely association of multidrug-resistance protein 2 single-nucleotide polymorphisms with tenofovir-induced renal adverse events.
J Infect Dis. 2007 May 1;195(9):1389-90; author reply 1390-1. doi: 10.1086/513282.
7
Tenofovir plasma concentrations in post-menopausal versus pre-menopausal HIV-infected women.
J Antimicrob Chemother. 2013 May;68(5):1206-7. doi: 10.1093/jac/dks519. Epub 2013 Jan 8.
8
Efficacy, safety and pharmacokinetics of tenofovir disoproxil fumarate in virologic-suppressed HIV-infected children using weight-band dosing.
Pediatr Infect Dis J. 2015 Apr;34(4):392-7. doi: 10.1097/INF.0000000000000633.
9
Toward a pharmacogenetic understanding of nucleotide and nucleoside analogue toxicity.
J Infect Dis. 2006 Dec 1;194(11):1471-4. doi: 10.1086/508550. Epub 2006 Oct 26.
10
Progression of renal impairment under therapy with tenofovir.
AIDS. 2005 Aug 12;19(12):1332-3. doi: 10.1097/01.aids.0000180109.03759.35.
引用本文的文献
1
Effect of Pregnancy and Concomitant Antiretrovirals on the Pharmacokinetics of Tenofovir in Women With HIV Receiving Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy Versus Women With HBV Receiving Tenofovir Disoproxil Fumarate Monotherapy.
J Clin Pharmacol. 2021 Mar;61(3):388-393. doi: 10.1002/jcph.1746. Epub 2020 Sep 22.
2
Plasma pharmacokinetics and urinary excretion of tenofovir following cessation in adults with controlled levels of adherence to tenofovir disoproxil fumarate.
Int J Infect Dis. 2020 Aug;97:365-370. doi: 10.1016/j.ijid.2020.06.037. Epub 2020 Jun 14.
3
Tenofovir Exposure during Pregnancy and Postpartum in Women Receiving Tenofovir Disoproxil Fumarate for the Prevention of Mother-to-Child Transmission of Hepatitis B Virus.
Antimicrob Agents Chemother. 2018 Nov 26;62(12). doi: 10.1128/AAC.01686-18. Print 2018 Dec.
4
Drug Transporter Genetic Variants Are Not Associated with TDF-Related Renal Dysfunction in Patients with HIV-1 Infection: A Pharmacogenetic Study.
PLoS One. 2015 Nov 4;10(11):e0141931. doi: 10.1371/journal.pone.0141931. eCollection 2015.
5
Plasma and Intracellular Pharmacokinetics of Tenofovir Disoproxil Fumarate 300 mg Every 48 Hours vs 150 mg Once Daily in HIV-Infected Adults With Moderate Renal Function Impairment.
Clin Infect Dis. 2015 Aug 15;61(4):633-9. doi: 10.1093/cid/civ346. Epub 2015 Apr 28.
本文引用的文献
1
Antiretrovirals and the kidney in current clinical practice: renal pharmacokinetics, alterations of renal function and renal toxicity.
AIDS. 2014 Mar 13;28(5):621-32. doi: 10.1097/QAD.0000000000000103.
2
ABCC2*1C and plasma tenofovir concentration are correlated to decreased glomerular filtration rate in patients receiving a tenofovir-containing antiretroviral regimen.
J Antimicrob Chemother. 2014 Aug;69(8):2195-201. doi: 10.1093/jac/dku129. Epub 2014 Apr 30.
3
Renal impairment in patients receiving a tenofovir-cART regimen: impact of tenofovir trough concentration.
J Acquir Immune Defic Syndr. 2013 Apr 1;62(4):375-80. doi: 10.1097/QAI.0b013e31827ce4ee.
4
Pregnancy-related effects on tenofovir pharmacokinetics: a population study with 186 women.
Antimicrob Agents Chemother. 2012 Feb;56(2):857-62. doi: 10.1128/AAC.05244-11. Epub 2011 Nov 28.
5
Impact of small body weight on tenofovir-associated renal dysfunction in HIV-infected patients: a retrospective cohort study of Japanese patients.
PLoS One. 2011;6(7):e22661. doi: 10.1371/journal.pone.0022661. Epub 2011 Jul 25.
6
Incidence and risk factors for tenofovir-associated renal function decline among Thai HIV-infected patients with low-body weight.
Curr HIV Res. 2010 Oct;8(7):504-9. doi: 10.2174/157016210793499259.
7
Pharmacogenetics of tenofovir treatment.
Pharmacogenomics. 2009 Oct;10(10):1675-85. doi: 10.2217/pgs.09.115.
8
Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study.
Clin Infect Dis. 2009 Jun 1;48(11):e108-16. doi: 10.1086/598507.
9
The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients.
Clin Pharmacol Ther. 2008 Feb;83(2):265-72. doi: 10.1038/sj.clpt.6100269. Epub 2007 Jun 27.
10
Estimation of population pharmacokinetic parameters of saquinavir in HIV patients with the MONOLIX software.
J Pharmacokinet Pharmacodyn. 2007 Apr;34(2):229-49. doi: 10.1007/s10928-006-9043-z. Epub 2007 Jan 9.
Zotero 插件